Company Filing History:
Years Active: 2016
Title: Innovator Nikolenta Kallinteris: Advancing Vaccine Technology
Introduction: Nikolenta Kallinteris, an accomplished inventor based in Framingham, MA, is recognized for his significant contribution to vaccine development. With one patent to his name, Kallinteris has focused on enhancing antigen presentation in hybrid peptide vaccines, a vital area in immunology and vaccine technology.
Latest Patents: Kallinteris holds a patent for "II-key/antigenic epitope hybrid peptide vaccines." This patent discloses a novel hybrid polypeptide designed to improve antigen presentation through a carefully structured combination. The design comprises three main elements: an N-terminal segment consisting of residues from the mammalian li-Key peptide, a flexible chemical structure linking the N-terminal element to an MHC Class II-presented epitope, and a C-terminal element featuring an antigenic epitope binding to the antigenic peptide binding site of an MHC class II molecule. This innovative approach may enhance immune responses and improve vaccine efficacy.
Career Highlights: Kallinteris is employed at Antigen Express, Inc., a company dedicated to developing advanced immunotherapeutic approaches. His work is part of a larger mission to create more effective vaccines that can respond to a variety of diseases. His expertise in peptide technology and immunology has positioned him at the forefront of vaccine innovation.
Collaborations: Throughout his career, Kallinteris has collaborated with other notable scientists and researchers in the field. Prominent colleagues, such as Robert E Humphreys and Minzhen Xu, have contributed to the advancement of research programs that seek to innovate vaccine technology and improve immune system responses.
Conclusion: Nikolenta Kallinteris is a noteworthy inventor whose work has the potential to significantly impact the field of vaccine development. His patent on the II-key/antigenic epitope hybrid peptide vaccines represents a step forward in enhancing antigen presentation, which could lead to improved vaccines and therapeutic options. As he continues his work at Antigen Express, Inc., Kallinteris remains committed to advancing medical science and public health through innovation.